Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

March 2015

Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment

Worldwide, at least 185 million people have been infected with hepatitis C virus (HCV), nearly three quarters of them in middle-income countries (MICs). Although hepatitis C can be easily treated and cured with oral drugs, over 700,000 people die from HCV-related complications each year. An estimated 30 million people need HCV treatment now, so they don’t progress to cirrhosis, liver failure or liver cancer... [Read More]


INPUD have written to the Executive Director and Deputy Director of UNITAID to express concern about the apparent intent of the Medicines Patent Pool to expand its mandate from HIV drugs to move into the market for the newly introduced Direct-Acting Antivirals for the treatment of hepatitis C.... [Read more]


A briefing, collaboratively written by several global groups and networks, which demonstrates the critical role of civil society in shaping the market for antiretroviral therapy and direct-acting antiretrovirals, is available here

File attachment: